# Osteoarthritis: Structural Endpoints for the Development of Drugs - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/osteoarthritis-structural-endpoints-for-the-development-of-drugs/8fba9dbf-fb3b-42a9-8837-a2ce4870eba1

> FDA guidance document: Osteoarthritis: Structural Endpoints for the Development of Drugs. Issue date: August 23, 2018. Get complete insights and analysis.

---

## Details

- Title: Osteoarthritis: Structural Endpoints for the Development of Drugs
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2018-08-23
- Comment Close Date: 2018-11-22
- Last Changed: 2020-05-15
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2018-D-2896">FDA-2018-D-2896</a>

## Related Documents

- [Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: Developing Drug and Biological Products in Oncology](https://www.globalkeysolutions.net/guidances/guidance-document/prevention-and-treatment-of-chemotherapy-induced-peripheral-neuropathy-developing-drug-and-biological-products-in-oncology/21c15304-ad79-4fb0-8609-1712f3c9952b)
- [Graft-versus-Host Diseases: Developing Drugs, Biological Products, and Certain Devices for Prevention or Treatment](https://www.globalkeysolutions.net/guidances/guidance-document/graft-versus-host-diseases-developing-drugs-biological-products-and-certain-devices-for-prevention-or-treatment/30eba576-b6ea-4536-918e-e634aefadcc4)
- [Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products — Content and Format](https://www.globalkeysolutions.net/guidances/guidance-document/dosage-and-administration-section-of-labeling-for-human-prescription-drug-and-biological-products-content-and-format/e2343785-81a2-4852-aba8-7ffd3a086deb)